Core Viewpoint - The announcement details the progress of share reduction by major shareholders of Jilin Xidian Pharmaceutical Technology Development Co., Ltd., indicating that the reduction will not affect the company's control structure or governance [3][5][20]. Summary by Sections Shareholder Reduction Details - The main entities involved in the share reduction are Hengqin Dingdian Equity Investment Fund Partnership (Limited Partnership) and its concerted actor Zhuhai Hengqin Runhuiyi Investment Partnership (Limited Partnership), who hold over 5% of the shares [3][4]. - The total shares to be reduced amount to a maximum of 2,294,700 shares, which is not more than 3% of the company's total share capital [4]. - As of November 3, 2025, a total of 765,019 shares have been reduced, representing 1.0001% of the total share capital [4][5]. Shareholding Structure - After the reduction, Hengqin Dingdian and Zhuhai Hengqin Runhuiyi collectively hold 7,649,396 shares, which is 9.9999% of the total share capital, still qualifying them as major shareholders [3][5]. - The shareholding percentage decreased from 11.0000% to 9.9999% following the reduction [5]. Impact on Company Governance - The reduction will not lead to any changes in the company's controlling shareholder or actual controller, nor will it significantly impact the company's governance structure or ongoing operations [3][20]. - The reduction process is compliant with pre-disclosure regulations and does not trigger a mandatory tender offer [7][8]. Future Plans - The shareholders may continue to reduce their holdings within the next 12 months, depending on their financial needs [16].
吉林省西点药业科技发展股份有限公司关于持股5%以上股东及其一致行动人减持股份进展暨权益变动的提示性公告